« Back
Home /
Raltegravir

Raltegravir

Item no.	HY-10353-25mg
Manufacturer	MedChem Express
CASRN	518048-05-0
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Food Safety Hormones Neuroscience Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.93
Citations	[1]Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62.\|[2]Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9\|[3]Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6\|[4]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72.\|[5]Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.\|[6]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692. Bioorg Med Chem. 2019 Sep 1;27(17):3836-3845. \|Clin Drug Investig. 2019 Mar;39(3):285-299. \|J Infect Dis. 2022 Sep 19;jiac386.\|J Mol Biol. 2022 Feb 22;167507.\|J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.\|J Virol. 2017 Jan 18;91(3). pii: e02152-16.\|Life Sci. 9 September 2022, 120948.\|Molecules. 2022 Dec 12;27(24):8829.\|Open Forum Infect Dis. 2024 Nov 29.\|PeerJ Physical Chemistry. 2019, 1:e6.\|Pharmaceuticals. 2023 Aug 8, 16(8), 1118.\|Phytomedicine. 2016 Nov 15;23(12):1383-1391. \|Preprints. 2024 Apr 23.\|Preprints. 2024 Feb 19.\|SSRN. 2023 Mar 30.\|Virol Sin. 2023 May 10;S1995-820X(23)00054-8.\|Virology. 2023 Jun 21.\|Viruses. 2021 Jan 18;13(1):E131.\|Viruses. 2024 Oct 13;16(10):1607.\|Plant Biosyst. 2018, 1-8.\|PLoS One. 2018 Mar 30;13(3):e0195168.
Smiles	O=C(C(O)=C(C(NCC1=CC=C(C=C1)F)=O)N=C2C(C)(C)NC(C3=NN=C(C)O3)=O)N2C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK-0518
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	HIV; HIV Integrase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	444.42
Product Description	Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
Manufacturer - Research Area	Infection; Cancer
Solubility	DMSO: ≥ 100 mg/mL
Manufacturer - Pathway	Anti-infection; Metabolic Enzyme/Protease
Isoform	HIV-1; HIV-2
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10353-25mg-safety-datasheet.pdf